Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
- 1.9k Downloads
Antiangiogenic therapy with vascular endothelial growth factor (VEGF) inhibitors is the current first-line treatment in metastatic renal cell carcinoma (mRCC). Immunotherapy with checkpoint inhibitor has been recently added to the armamentarium of mRCC treatment. These therapies are based on treatment with antibodies that block programmed cell death-1 (PD-1), programmed cell death ligand 1 (PD-L1) pathways, demonstrating impressive response rates and improved survival in several tumour types. So far, nivolumab is the only approved anti-PD-1 monoclonal antibody after VEGF therapy in mRCC. According to preclinical and clinical studies, combination therapies with VEGF- and checkpoint inhibitors have synergistic effect achieving improved response rates. However, toxicity in some combinations is high. In this article, we present a review of the ongoing trials with these drug combinations for RCC.
KeywordsAngiogenesis inhibitors Cell cycle checkpoints Drug combinations Immunotherapy Renal cancer
We would like to thank the European Urological Scholarship Programme for financially supporting the research fellowship of TK and NG at Antoni van Leeuwenhoek Hospital/the Netherlands Cancer Institute in Amsterdam, the Netherlands.
The authors declare that they have no relevant financial interests.
Conflict of interest
AB took part in advisory boards of Pfizer, Novartis, Ipsen, Eisai and Roche. He is the PI of the EORTC SURTIME trial sponsored in part by a Grant from Pfizer to the EORTC. LA has received consulting and advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding from Pfizer and Novartis. BE has received fees for serving on advisory boards from Pfizer, Novartis, Bristol-Myers Squibb, Exelixis, and Roche and lecture fees from Pfizer and Novartis. JH has consulted or has an advisory role for MSD Oncology, Pfizer, and Bristol-Myers Squibb, as well as gained research funding by MSD and Bristol-Myers Squibb. TP is a company consultant for Novartis, Pfizer, GSK, has received company speaker honoraria from Novartis, Pfizer, GSK, Genentech, performed trial participation for GSK, Pfizer, BMS, Genentech, Genetech, and received grants/research support from GSK, Pfizer, and Novartis. The other authors have no conflict of interest to declare.
- 9.Fisher RI, Rosenberg SA, Fyfe G et al (2000) Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6(1):55–57Google Scholar
- 30.Guislain A, Gadiot J, Kaiser A et al (2015) Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother 2015. Cancer Immunol Immunother 64(10):1241–1250CrossRefPubMedGoogle Scholar
- 35.ClinicalTrials.gov (NCT02298959) Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid TumorsGoogle Scholar
- 36.Taylor M, Dutcus CE, Schmidt E et al (2016) A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients with selected solid tumors. Ann Oncol 27(6):266–295Google Scholar
- 37.Clinicaltrials.gov (NCT02811861) Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell CarcinomaGoogle Scholar
- 39.Atkins MB, Plimack ER, Puzanov I et al (2016) Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): preliminary safety and efficacy results. Ann Oncol 27(6):266–295Google Scholar
- 40.Larkin JMG, Gordon MS, Thistlethwaite F, et al (2016) Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. J Clin Oncol 34(Abstract TPS4580)Google Scholar
- 41.Clinicaltrials.gov (KEYNOTE-426 NCT02853331) Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)Google Scholar
- 42.Clinicaltrials.gov (JAVELIN Renal 101 NCT02684006) A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)Google Scholar
- 44.McDermott DF, Atkins MB, Motzer RJ, et al (2017) A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). Paper presented at: 2017 Genitourinary Cancers Symposium; February 16–18, 2017; Orlando, FLGoogle Scholar
- 45.Clinicaltrials.gov (IMmotion 151 NCT02420821) A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell CarcinomaGoogle Scholar
- 47.ClinicalTrials.gov (NCT02724878) Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaGoogle Scholar
- 48.ClinicalTrials.gov (NCT02819596) MEDI4736 Combinations in Metastatic Renal Cell Carcinoma (CALYPSO)Google Scholar
- 49.Apolo A, Mortazavi A, Stein M, et al (2017) A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. J Clin Oncol 35, 2017 (suppl 6S; abstract 293)Google Scholar
- 52.ClinicalTrials.gov (NCT02212730) A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)Google Scholar
- 53.ClinicalTrials.gov (NCT02575222) Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell CarcinomaGoogle Scholar
- 54.ClinicalTrials.gov (NCT02446860) A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR) (ADAPTeR)Google Scholar
- 55.ClinicalTrials.gov (NCT02210117) Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)Google Scholar
- 59.ClinicalTrials.gov (NCT03024996) A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010)Google Scholar